Compare $GALT vs $MYGN | Chartloom

Compare

$GALT vs $MYGN

Galectin Therapeutics Inc · Myriad Genetics Inc

GALT

Galectin Therapeutics Inc

MYGN

Myriad Genetics Inc

Compare $GALT vs $MYGN

Comparing Galectin Therapeutics Inc and Myriad Genetics Inc

GALTGalectin Therapeutics Inc

MYGNMyriad Genetics Inc

GALTGalectin Therapeutics Inc

Market cap

$259M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-2.7%

52W performance

-16.9%

FCF yield

-6.1%

MYGNMyriad Genetics Inc

Market cap

$407M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.50x

Rev growth (TTM)

-3.2%

YTD performance

-29.8%

52W performance

-43.6%

FCF yield

-3.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GALT

MYGN

Detailed metrics comparison

GALT

Galectin Therapeutics Inc

MYGN

Myriad Genetics Inc

Market Cap

GALT$259M

MYGN$407M

Enterprise Value

GALT$384M

MYGN$413M

Price

GALT$3.94

MYGN$4.31

P/E Ratio

GALTN/A

MYGNN/A

P/S Ratio

GALT0.00x

MYGN0.50x

EV/Sales

GALT0.00x

MYGN0.51x

EV/EBITDA

GALT0.00x

MYGN49.97x

P/B Ratio

GALT150.12x

MYGN1.43x

P/FCF Ratio

GALTN/A

MYGNN/A

EV/FCF

GALT-24.16x

MYGN-29.05x

PEG Ratio

GALTN/A

MYGNN/A

Forward P/E (NTM)

GALTN/A

MYGNN/A

Forward P/S (NTM)

GALTN/A

MYGN0.50x

Revenue (TTM)

GALT$0

MYGN$807M

Revenue Growth (YoY)

GALTN/A

MYGN-3.2%

Forward Rev Growth

GALT0.0%

MYGN5.6%

Gross Margin (TTM)

GALT0.0%

MYGN68.8%

Operating Margin (TTM)

GALT0.0%

MYGN0.0%

EBITDA Margin (TTM)

GALT0.0%

MYGN-5.0%

Net Margin (TTM)

GALT0.0%

MYGN-14.0%

FCF Margin (TTM)

GALTN/A

MYGN-1.8%

Net Income (TTM)

GALT$-28M

MYGN$-113M

FCF (TTM)

GALT$-16M

MYGN$-14M

EPS (TTM)

GALT-$0.43

MYGN-$1.19

ROE (TTM)

GALT-25862.0%

MYGN-3259.0%

ROA (TTM)

GALT-17683.0%

MYGN-1639.0%

ROIC (TTM)

GALT-11607.0%

MYGN-2418.0%

Cash

GALT$13M

MYGN$115M

Debt

GALT$138M

MYGN$121M

Net Cash/Debt

GALT$-124M

MYGN$-6M

Current Ratio (TTM)

GALT0.10x

MYGN2.21x

Quick Ratio (TTM)

GALT0.09x

MYGN1.72x

Debt/Equity (TTM)

GALT11.09x

MYGN0.40x

Debt/Assets (TTM)

GALT0.0%

MYGN0.0%

Interest Coverage (TTM)

GALTN/A

MYGNN/A

Net Debt/EBITDA (TTM)

GALT0.00x

MYGN0.00x

Beta

GALT0.50

MYGN1.68

52W Performance

GALT-16.9%

MYGN-43.6%

YTD Performance

GALT-2.7%

MYGN-29.8%

% from 52W High

GALT-44.7%

MYGN-49.8%

% from 52W Low

GALT94.6%

MYGN57.3%

Asset Turnover (TTM)

GALT0.00x

MYGN1.17x

FCF Yield (TTM)

GALT-6.1%

MYGN-3.5%

Earnings Yield (TTM)

GALT-10.8%

MYGN-27.7%

Dividend Yield (TTM)

GALTN/A

MYGNN/A

Rule of 40

GALT0.0

MYGN-4.9

EV/GP/RG

GALTN/A

MYGN1.67

Ticker research

View GALT research View MYGN research

Metric	GALT Galectin Therapeutics Inc	MYGN Myriad Genetics Inc
Market & Valuation
Market Cap	$259M	$407M
Enterprise Value	$384M	$413M
Price	$3.94	$4.31
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.50x
EV/Sales	0.00x	0.51x
EV/EBITDA	0.00x	49.97x
P/B Ratio	150.12x	1.43x
P/FCF Ratio	N/A	N/A
EV/FCF	-24.16x	-29.05x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.50x
Revenue & Growth
Revenue (TTM)	$0	$807M
Revenue Growth (YoY)	N/A	-3.2%
Forward Rev Growth	0.0%	5.6%
Profitability
Gross Margin (TTM)	0.0%	68.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-5.0%
Net Margin (TTM)	0.0%	-14.0%
FCF Margin (TTM)	N/A	-1.8%
Net Income (TTM)	$-28M	$-113M
FCF (TTM)	$-16M	$-14M
EPS (TTM)	-$0.43	-$1.19
ROE (TTM)	-25862.0%	-3259.0%
ROA (TTM)	-17683.0%	-1639.0%
ROIC (TTM)	-11607.0%	-2418.0%
Financial Health
Cash	$13M	$115M
Debt	$138M	$121M
Net Cash/Debt	$-124M	$-6M
Current Ratio (TTM)	0.10x	2.21x
Quick Ratio (TTM)	0.09x	1.72x
Debt/Equity (TTM)	11.09x	0.40x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.50	1.68
52W Performance	-16.9%	-43.6%
YTD Performance	-2.7%	-29.8%
% from 52W High	-44.7%	-49.8%
% from 52W Low	94.6%	57.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.17x
FCF Yield (TTM)	-6.1%	-3.5%
Earnings Yield (TTM)	-10.8%	-27.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-4.9
EV/GP/RG	N/A	1.67
Ticker research	View GALT research	View MYGN research

Valuation

P/S Ratio

GALT

0.00x

MYGN

0.50x

EV/FCF

MYGN

-29.05x

GALT

-24.16x

Growth & revenue

Revenue Growth TTM

MYGN

-3.2%

Forward Revenue Growth

MYGN

5.6%

GALT

0.0%

Profitability & performance

Gross Margin

MYGN

68.8%

GALT

0.0%

ROE

MYGN

-3259.0%

GALT

-25862.0%

FCF Yield %

MYGN

-3.5%

GALT

-6.1%

52-Week Performance

GALT

-16.9%

MYGN

-43.6%

Detailed metrics comparison

GALT

Galectin Therapeutics Inc

MYGN

Myriad Genetics Inc

Market Cap

GALT$259M

MYGN$407M

Enterprise Value

GALT$384M

MYGN$413M

Price

GALT$3.94

MYGN$4.31

P/E Ratio

GALTN/A

MYGNN/A

P/S Ratio

GALT0.00x

MYGN0.50x

EV/Sales

GALT0.00x

MYGN0.51x

EV/EBITDA

GALT0.00x

MYGN49.97x

P/B Ratio

GALT150.12x

MYGN1.43x

P/FCF Ratio

GALTN/A

MYGNN/A

EV/FCF

GALT-24.16x

MYGN-29.05x

PEG Ratio

GALTN/A

MYGNN/A

Forward P/E (NTM)

GALTN/A

MYGNN/A

Forward P/S (NTM)

GALTN/A

MYGN0.50x

Revenue (TTM)

GALT$0

MYGN$807M

Revenue Growth (YoY)

GALTN/A

MYGN-3.2%

Forward Rev Growth

GALT0.0%

MYGN5.6%

Gross Margin (TTM)

GALT0.0%

MYGN68.8%

Operating Margin (TTM)

GALT0.0%

MYGN0.0%

EBITDA Margin (TTM)

GALT0.0%

MYGN-5.0%

Net Margin (TTM)

GALT0.0%

MYGN-14.0%

FCF Margin (TTM)

GALTN/A

MYGN-1.8%

Net Income (TTM)

GALT$-28M

MYGN$-113M

FCF (TTM)

GALT$-16M

MYGN$-14M

EPS (TTM)

GALT-$0.43

MYGN-$1.19

ROE (TTM)

GALT-25862.0%

MYGN-3259.0%

ROA (TTM)

GALT-17683.0%

MYGN-1639.0%

ROIC (TTM)

GALT-11607.0%

MYGN-2418.0%

Cash

GALT$13M

MYGN$115M

Debt

GALT$138M

MYGN$121M

Net Cash/Debt

GALT$-124M

MYGN$-6M

Current Ratio (TTM)

GALT0.10x

MYGN2.21x

Quick Ratio (TTM)

GALT0.09x

MYGN1.72x

Debt/Equity (TTM)

GALT11.09x

MYGN0.40x

Debt/Assets (TTM)

GALT0.0%

MYGN0.0%

Interest Coverage (TTM)

GALTN/A

MYGNN/A

Net Debt/EBITDA (TTM)

GALT0.00x

MYGN0.00x

Beta

GALT0.50

MYGN1.68

52W Performance

GALT-16.9%

MYGN-43.6%

YTD Performance

GALT-2.7%

MYGN-29.8%

% from 52W High

GALT-44.7%

MYGN-49.8%

% from 52W Low

GALT94.6%

MYGN57.3%

Asset Turnover (TTM)

GALT0.00x

MYGN1.17x

FCF Yield (TTM)

GALT-6.1%

MYGN-3.5%

Earnings Yield (TTM)

GALT-10.8%

MYGN-27.7%

Dividend Yield (TTM)

GALTN/A

MYGNN/A

Rule of 40

GALT0.0

MYGN-4.9

EV/GP/RG

GALTN/A

MYGN1.67

Ticker research

View GALT research View MYGN research

Metric	GALT Galectin Therapeutics Inc	MYGN Myriad Genetics Inc
Market & Valuation
Market Cap	$259M	$407M
Enterprise Value	$384M	$413M
Price	$3.94	$4.31
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.50x
EV/Sales	0.00x	0.51x
EV/EBITDA	0.00x	49.97x
P/B Ratio	150.12x	1.43x
P/FCF Ratio	N/A	N/A
EV/FCF	-24.16x	-29.05x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.50x
Revenue & Growth
Revenue (TTM)	$0	$807M
Revenue Growth (YoY)	N/A	-3.2%
Forward Rev Growth	0.0%	5.6%
Profitability
Gross Margin (TTM)	0.0%	68.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-5.0%
Net Margin (TTM)	0.0%	-14.0%
FCF Margin (TTM)	N/A	-1.8%
Net Income (TTM)	$-28M	$-113M
FCF (TTM)	$-16M	$-14M
EPS (TTM)	-$0.43	-$1.19
ROE (TTM)	-25862.0%	-3259.0%
ROA (TTM)	-17683.0%	-1639.0%
ROIC (TTM)	-11607.0%	-2418.0%
Financial Health
Cash	$13M	$115M
Debt	$138M	$121M
Net Cash/Debt	$-124M	$-6M
Current Ratio (TTM)	0.10x	2.21x
Quick Ratio (TTM)	0.09x	1.72x
Debt/Equity (TTM)	11.09x	0.40x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.50	1.68
52W Performance	-16.9%	-43.6%
YTD Performance	-2.7%	-29.8%
% from 52W High	-44.7%	-49.8%
% from 52W Low	94.6%	57.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.17x
FCF Yield (TTM)	-6.1%	-3.5%
Earnings Yield (TTM)	-10.8%	-27.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-4.9
EV/GP/RG	N/A	1.67
Ticker research	View GALT research	View MYGN research